Damora Therapeutics (DMRA) Stock Forecast & Price Target
Score
Damora Therapeutics, Inc. price target
| DMRA | |
|---|---|
| Low | $40.00 |
| Average | $52.50 |
| High | $60.00 |
| Upside vs current price | +143.1% |
The average target of $52.50 is +143.1% versus the current DMRA price of $21.60.
Damora Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 9 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
10 analysts cover DMRA.
Damora Therapeutics, Inc. EPS and revenue estimates
The estimate table for the Damora Therapeutics, Inc. keeps 2026 EPS $-2.00, 2027 EPS $-2.15, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-2.00 | — |
| 2027 | $-2.15 | — |
Is Damora Therapeutics, Inc. a buy or sell?
Of the 10 analysts covering Damora Therapeutics, Inc., 10 rate it a buy (1 strong buy and 9 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The DMRA consensus label is Buy, beside 10 buy-side ratings and 0 sell-side ratings.
The average target of $52.50 implies +143.1% versus the current price of $21.60.
the Damora Therapeutics, Inc. closes with 10 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Damora Therapeutics, Inc. forecast
Between the DMRA low of $40.00 and the high of $60.00, the average target is $52.50.
From today's $21.60 print, the DMRA average target is +143.1% away.
Most of the DMRA coverage agrees: 10 of 10 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
Earnings estimates for DMRA are falling: 2026 $-2.00, then 2027 $-2.15.
DMRA coverage is thin at 10 analysts, and one revision moves the average.
Damora Therapeutics, Inc. forecast questions
What is the DMRA price target?
The published range for DMRA is $40.00 to $60.00, with an average of $52.50. That average is +143.1% versus the current price of $21.60.
Is Damora Therapeutics, Inc. a buy or sell?
Of the 10 analysts covering Damora Therapeutics, Inc., 10 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for DMRA is 10 on the buy side, 0 at hold, and 0 on the sell side.
What is the EPS estimate for Damora Therapeutics, Inc.?
Analyst EPS estimates for Damora Therapeutics, Inc.: 2026 $-2.00, 2027 $-2.15.
What is the revenue estimate for Damora Therapeutics, Inc.?
No revenue estimate with at least 3 analysts is on file for Damora Therapeutics, Inc..
How many analysts cover DMRA?
10 analysts cover DMRA. Their consensus on DMRA is Buy, across those 10.